Novartis reports positive topline results from second Phase III trial of Beovu® in patients with diabetic macular edema – IT Business Net
In Phase III KESTREL study , Beovu (brolucizumab 6 mg) achieved its primary endpoint of non-inferiority to aflibercept 2 mg in change in best-corrected visual acuity (BCVA) at year one (week 52) 1 In a secondary endpoint, more than half of Beovu patients in the 6 mg arm were maintained on a three-month dosing interval through year one, following the loading phase 1 Significant improvement with Beovu 6 mg in change of central subfield thickness (CST) from baseline over the period of week 40 through week 52 was observed 1 1 Novartis intends to submit the data from KESTREL, together with the da...
Source: itbusinessnet.com